The latest price target for Amgen (NASDAQ:AMGN) was reported by UBS on April 13, 2026. The analyst firm set a price target for $400.00 expecting AMGN to rise to within 12 months (a possible 15.04% upside). 45 analyst firms have reported ratings in the last year.

The latest analyst rating for Amgen (NASDAQ:AMGN) was provided by UBS, and Amgen maintained their buy rating.

The last upgrade for Amgen Inc happened on May 3, 2024 when William Blair raised their price target to N/A. William Blair previously had a market perform for Amgen Inc.

The last downgrade for Amgen Inc happened on February 12, 2026 when Freedom Broker changed their price target from $360 to $375 for Amgen Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amgen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amgen was filed on April 13, 2026 so you should expect the next rating to be made available sometime around April 13, 2027.

While ratings are subjective and will change, the latest Amgen (AMGN) rating was a maintained with a price target of $390.00 to $400.00. The current price Amgen (AMGN) is trading at is $347.70, which is out of the analyst’s predicted range.